(E)-3-[6-[[(2,6-Dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2- propenoic Acid: A High-Affinity Leukotriene B₄ Receptor Antagonist with Oral Antiinflammatory Activity

Citations Over TimeTop 10% of 1996 papers

Abstract

An extensive structure-activity study based around the high-affinity leukotriene B4 (LTB4) receptor antagonist SB 201146 (1) led to the identification of (E)-3-[6-[[(2,6-dichlorophenyl)-thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid (3). This compound displays high affinity for the human neutrophil LTB4 receptor (Ki = 0.78 nM), blocks LTB4-induced Ca2+ mobilization with an IC50 of 6.6 +/- 1.5 nM, and demonstrates potent oral and topical antiinflammatory activity in a murine model of dermal inflammation.

Related Papers

• → Synthesis, molecular docking and α-glucosidase inhibition of 2-((5,6-diphenyl-1,2,4-triazin-3-yl)thio)-N-arylacetamides(2017)38 cited
• → (E)-3-[6-[[(2,6-Dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2- propenoic Acid: A High-Affinity Leukotriene B₄ Receptor Antagonist with Oral Antiinflammatory Activity(1996)21 cited
• → Pharmacological profile of a novel, orally active leukotriene B4 antagonist, SM-15178(1994)8 cited
• → WF11605, an antagonist of leukotriene B4 produced by a fungus. I. Producing strain, fermentation, isolation and biological activity.(1992)8 cited
• → Pharmacological profiles of a potential LTB4-antagonist, SM-9064(1986)25 cited